Halozyme Therapeutics (HALO) Income towards Parent Company (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Income towards Parent Company data on file, last reported at $150.0 million in Q1 2026.

• On a quarterly basis, Income towards Parent Company rose 27.06% year-over-year to $150.0 million in Q1 2026; TTM through Mar 2026 was $348.9 million, a 28.12% decrease from a year earlier, with the FY2025 full-year figure at $316.9 million, down 28.64% from the prior year.
• Income towards Parent Company for Q1 2026 stood at $150.0 million, up from -$141.6 million in the prior quarter.
• Over the last five years, Income towards Parent Company for HALO reached as high as $175.3 million in Q3 2025 and fell as low as -$141.6 million in Q4 2025.
• Historically, Income towards Parent Company has averaged $82.0 million across 5 years, with a median of $81.8 million in 2023.
• Across the five-year window, Income towards Parent Company soared 229.53% in 2023 and slumped 203.34% in 2025, its largest moves.
• Year by year, Income towards Parent Company stood at $57.7 million in 2022, then surged by 47.98% to $85.4 million in 2023, then surged by 60.46% to $137.0 million in 2024, then slumped by 203.34% to -$141.6 million in 2025, then jumped by 205.97% to $150.0 million in 2026.
• Per Business Quant data, the three most recent Income towards Parent Company figures were $150.0 million in Q1 2026, -$141.6 million in Q4 2025, and $175.3 million in Q3 2025.